|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018(English version)显示文摘Contents1. General guidelines for diagnosis and treatment of colorectal cancer2. Diagnostic principles for colorectal cancer2.1 Colorectal cancer screening of asymptomatic healthy population2.2 Basic diagnostic principles2.2.1 Colorectal cancer diagnosis2.2.2 Appendix on colorectal cancer imaging staging and diagnosis2.3 Principles of pathological diagnosis2.4 Staging. | Chinese Society of Clinical Oncology(CSCO)diagnosis and treatment guidelines for colorectal cancer working group Suzhan Zhang Jin Li Sanjun Cai Ruihua Xu Zhen Zhang | 2019 | Chinese Journal of Cancer Research2019，31，1： | 66 |
| 2 | Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020显示文摘Colorectal cancer(CRC) is one of the major cancers threatening life and health of Chinese residents. According to the latest data released by the National Cancer Center in2015(1), there were 387,000 new cases and 187,100 deaths of CRC in China, accounting for 9.87% and 8.01% of all malignancies. The first version of the Chinese Society of Clinical Oncology(CSCO) guidelines was released in April2017, and has been updated annually based on the latest clinical research data and the availability of new drugs(2-4). Here, we present the main updates of the 2021 version compared to 2020 version. | Caixia Dong Yuwei Ding Shanshan Weng Guichao Li Yanqing Huang Hanguang Hu Zhen Zhang Suzhan Zhang Ying Yuan | 2021 | Chinese Journal of Cancer Research2021，33，3： | 19 |
| 3 | CSCO guidelines for colorectal cancer version 2022:Updates and discussions显示文摘Colorectal cancer(CRC) is the third most common cancer worldwide and the second most common in tumor-related mortality by Global Cancer Statistics 2020(1). Recent data show that the incidence and mortality of CRC in China are increasing(2-4), with the number of new cases and deaths reaching 607,900 and 261,777 in 2019. | Zhijun Yuan Shanshan Weng Chenyang Ye Hanguang Hu Suzhan Zhang Ying Yuan | 2022 | Chinese Journal of Cancer Research2022，34，2： | 16 |
| 4 | Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology显示文摘Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously.Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(CSCO) and the China Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation. | Xuchao Zhang Zhiyong Liang Shengyue Wang Shun Lu Yong Song Ying Cheng Jianming Ying Weiping Liu Yingyong Hou Yangqiu Li Yi Liu Jun Hou Xiufeng Liu Jianyong Shao Yanhong Tai Zheng Wang Li Fu Hui Li Xiaojun Zhou Hua Bai Mengzhao Wang You Lu Jinji Yang Wenzhao Zhong Qing Zhou Xuening Yang Jie Wang Cheng Huang Xiaoqing Liu Xiaoyan Zhou Shirong Zhang Hongxia Tian Yu Chen Ruibao Ren Ning Liao Chunyan Wu Zhongzheng Zhu Hongming Pan Yanhong Gu Liwei Wang Yunpeng Liu Suzhan Zhang Tianshu Liu Gong Chen Zhimin Shao Binghe Xu Qingyuan Zhang Ruihua Xu Lin Shen Yilong Wu | 2019 | Cancer Biology & Medicine2019，16，1： | 14 |
| 5 | Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer显示文摘Oxaliplatin 是在 colorectal 癌症(CRC ) 的化疗的关键药。然而,它的功效由于癌症房间的药抵抗是未得到满足的。在这研究,我们测试了是否一个自然代理人, ursolic 酸,能为 CRC 提高 oxaliplatin 的功效。当在 vitro 模型,和 SW620 异种皮移植老鼠模型被使用在,包括 SW480, SW620, LoVo,和 RKO 的四根 CRC 房间线被使用进一步在里面 vivo 学习。我们发现 ursolic 酸禁止了增长并且导致了所有四个房间的 apoptosis 并且提高了 oxaliplatin 的 cytotoxicity。这效果与 Bcl-xL 的下面规定被联系, Bcl-2 , survivin , caspase-3 的激活, 8 , 9 ,并且 MAPK 的 KRAS 表示和 BRAF , MEK1/2 , ERK1/2 , p-38 , JNK , AKT , IKK , IB ,和 p65 phosphorylation 的抑制, PI3K/AKT ,并且 NF-B 发信号小径。二个代理人也在 vivo 对肿瘤生长显示出 synergistic 效果。另外, ursolic 酸恢复了与 oxaliplatin 对待的鼠标的肝函数和身体重量。因此,我们断定 ursolic 酸能在 vitro 并且在 vivo 对 CRC 提高 oxaliplatin 的治疗学的效果,它提供有效策略最小化导致 oxaliplatin 的不利事件的负担并且提供地基让新临床的策略对待 CRC。 | Jianzhen Shan Yanyan Xuan QiZhang Chunpeng Zhu Zhen Liu Suzhan Zhang | 2016 | Protein & Cell2016，7，8： | 11 |
| 6 | Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019显示文摘According to the latest data released by the National Cancer Center,colorectal cancer(CRC)had the third highest incidence and the fifth highest mortality of all malignancies,with 388,000 new cases and 187,000 cancer deaths in China(1).The Chinese Society of Clinical Oncology(CSCO)originally published the English version of 2018 guideline concerning CRC and updated them in2019(2,3).According to the latest progress,clinical guidelines have been updated.Here,we present the main updates of the 2020 version compared to 2019 version. | Shanshan Weng Ying Yuan Xicheng Wang Gong Chen Yi Wang Weiqi Sheng Xinxiang Li Aiping Zhou Zhen Zhang Guichao Li Sanjun Cai Ruihua Xu Jin Li Suzhan Zhang | 2020 | Chinese Journal of Cancer Research2020，32，3： | 4 |
| 7 | Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018显示文摘According to the latest data from cancer registration center, there are estimated to be 3,929,000 individuals newly diagnosed with cancer and 2,338,000 deaths from this disease in China in 2015 (1). Among them, colorectal cancer (CRC) with 388,000 newly diagnosed cases and 187,000 deaths, stands the third place in incidence and the fifth place in mortality. The Chinese Society of Clinical Oncology (CSCO) has organized an expert committee to write and publish the Guideline for Colorectal Cancer in 2017. And its English version has already been published in March 2019 (2). According to the latest progress, the expert committee updated the guideline to the 2019 version in this April, and the summary of the main updates are as following. | Ying Yuan Xicheng Wang Gong Chen Yi Wang Weiqi Sheng Xinxiang Li Aiping Zhou Zhen Zhang Guichao Li Sanjun Cai Ruihua Xu Jin Li Suzhan Zhang | 2019 | Chinese Journal of Cancer Research2019，31，3： | 4 |
| 8 | Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer:A prospective,multicenter,observational,non-interventional phaseⅣtrial显示文摘Objective:Bevacizumab has an important and evolving role in improving outcomes in patients with metastatic colorectal cancer(mCRC)worldwide and was approved in China in 2010.However,there are limited real-world data on the efficacy and safety of chemotherapy regimens combined with bevacizumab in Chinese patients with mCRC.This observational,phase IV trial study aimed to obtain more experience on the efficacy and safety of bevacizumab combined with chemotherapy in Chinese mCRC patients.Methods:Between September 2013 and November 2016,patients with histologically confirmed mCRC were enrolled in a prospective,multicenter,observational,non-interventional phase IV trial at 26 centers across China.Eligible patients received different chemotherapeutic regimens combined with bevacizumab.The efficacy and safety data in the intention-to-treat study population were analyzed.Results:A total of 611 patients were included in the efficacy analysis.The median overall survival and median progression-free survival was 18.00 and 10.05 months,respectively.The objective response rate was 21.00%and disease control rate was 89.40%.In subgroup analyses,the survival differences were observed according to metastatic status,duration of treatment and elevation in blood pressure.A total of 613 patients were evaluable for safety assessments.And 569(92.82%)patients reported at least one adverse event(AE),and 151(24.63%)experienced grade 3 or higher AEs.The incidence of bevacizumab-associated AEs of special interest was reported in 31(5.06%)patients with hypertension(n=12),abscesses and fistulae(n=7),bleeding(n=6),proteinuria(n=3),gastrointestinal perforation(n=2)and venous thrombotic events(n=1).Conclusions:This observational phase IV trial broadens our experience and knowledge of bevacizumab in the Chinese population and provides a good indication of its overall efficacy and safety.Bevacizumab in combination with chemotherapy offers clinical benefits to Chinese patients with mCRC and has an acceptable and manageable safety profile. | Fenghua Wang Guanghai Dai Yanhong Deng Yong Tang Wei Wang Zuoxing Niu Feng Bi Liangjun Zhu Zengqing Guo Jin Yan Bing Hu Min Tao Shujun Yang Suzhan Zhang Lu Wen Ruihua Xu | 2021 | Chinese Journal of Cancer Research2021，33，4： | 2 |
| 9 | Cluster Randomization Trial of Sequence Mass Screening for Colorectal Cancer显示文摘 | Shu Zheng M.D. Kun Chen M.D. Xiyong Liu M.D. Xinyuan Ma M.D. Hai Yu Ph.D. Kang Chen Kaiyan Yao Lun Zhou M.D. Linbo Wang M.D. Peiling Qiu M.D. Yongchuan Deng M.D. Suzhan Zhang M.D | 2003 | Diseases of the Colon & Rectum2003，，1： | 1 |
| 10 | SELDI-TOF-MS:the proteomics and bioinformatics approaches in the diagnosis of breast cancer显示文摘 | Hu Y Suzhan Zhang Jiekai Yu | 2005 | Breast2005，14，4： | 1 |
| 11 | Function and mode of action of cytohesins in the epidermal growth factorpathway in colorectal cancer cells显示文摘 | Tao Pan Junfeng Sun Jun Zhou Zhixuan Fu Yiwang Hu Shu Zheng Suzhan Zhang | 2013 | Oncology Letters2013，，2： | 1 |
| 12 | 含铂化疗对EGFR-TKIs敏感性影响机制的研究进展(英文)显示文摘In the past decade,the advent of the epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)has dramatically influenced the therapeutic strategies for treating lung cancer,but with tumor progression and drug resistance,patients will ultimately develop reduced sensitivity to EGFR-TKIs.How can we delay the emergence of drug resistance? What is the next strategy after drug resistance? How to reasonably combine platinum-based chemotherapy and EGFR-TKIs? These questions are currently the focus of lung cancer research.Clinical studies have reported that platinum-based chemotherapy can increase the sensitivity to EGFR-TKIs.However,results of pre-clinical and clinical studies have been inconsistent.The mechanisms of platinum chemotherapy and EGFR-TKIs are still unknown due to the lack of systematic research.Therefore,systematic studies are required to show the mechanisms of EGFR-TKIs and chemotherapy agents and define the markers sensitive to their combinations when given concurrently or sequentially. | Chi Pan Suzhan Zhang Jianjin Huang | 2013 | The Chinese-German Journal of Clinical Oncology2013，12，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员